Ken Griffin Kronos Bio, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Kronos Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 31,400 shares of KRON stock, worth $32,342. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,400
Previous 4,800
554.17%
Holding current value
$32,342
Previous $6,000
533.33%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding KRON
# of Institutions
58Shares Held
20.7MCall Options Held
31.4KPut Options Held
0-
Vida Ventures Advisors, LLC2.77MShares$2.85 Million5.96% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.92MShares$1.98 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.86MShares$1.91 Million0.0% of portfolio
-
Partners Capital Investment Group, LLP Boston, MA1.67MShares$1.72 Million0.04% of portfolio
-
Alphabet Inc. Mountain View, CA1.44MShares$1.48 Million0.11% of portfolio
About Kronos Bio, Inc.
- Ticker KRON
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,769,100
- Market Cap $58.5M
- Description
- Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...